DIRECT ORAL ANTICOAGULANTS
Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications. They provide alternatives to low molecular weight heparin in a peri-operative setting for venous thrombo...
Saved in:
Main Authors: | I. Tzoran (Author), B. Brenner (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2016-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants
by: A. I. Mironova, et al.
Published: (2022) -
Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
by: Dopsaj Violeta
Published: (2020) -
Direct oral anticoagulants: A new chapter in anticoagulation therapy
by: Stepanović-Petrović Radica, et al.
Published: (2020) -
Specific Antidotes for Direct Oral Anticoagulants in Life-Threatening Bleeding
by: A. B. Sumarokov, et al.
Published: (2019) -
The risk of bleeding minimization with direct oral anticoagulants
by: Т. N. Novikova
Published: (2021)